fashion -WSS

fashion

author：focus 2025-10-01 00:46:50 - browse：967

STAT's Casey Ross (left) and Kimberly Powell, NVIDIA's vice president for healthcare at the STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — In the world of drug discovery, AI progress is often measured by a single-mile marker: When will we get an AI-designed drug?

The answer remains, ambiguously, “the future,” but at STAT’s Breakthrough Summit leaders from NVIDIA and Google insisted that the impact of AI is visible today.

Kimberly Powell, vice president of healthcare for NVIDIA, pointed to an increase in investigational new drug applications filed with the Food and Drug Administration that cite AI, as well as an uptick in early-stage readouts from clinical trials, as evidence of progress. Some of the recent readouts, Powell said, show that what’s going into Phase 1 clinical trials is more successful.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Obamacare plans could cover weight loss drugs

explore

WSS

Elevance, SCAN deals highlight health insurer acquisition scrutiny

In 'major milestone,' FDA approves first cell therapy for solid tumors

Data don't support strong claims for Covid

Flagship Pioneering startup Sonata Therapeutics lays off 21

Data don't support strong claims for Covid

FDA approves Moderna’s RSV vaccine, its second licensed product

entertainment

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

Apple is now the first public company to be valued at $3 trillion

Sutter Health’s antitrust win overturned by appeals court

Psychedelics group wrestles with new pharma identity

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Walensky prepares to leave CDC — and Congress — behind

WATCH: Why do our ears pop?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

A new initiative will help leaders fight the next pandemic

State Dept. review finds Biden bears some blame for Afghanistan failures

Weight loss drugs aren’t covered by Obamacare. That may change

focus

FDA approves Moderna’s RSV vaccine, its second licensed product

Surprise medical billing ban raises prices elsewhere

Structure Therapeutics oral GLP

Senators tussle over abortion against the backdrop of a presidential campaign

Elevance PBM president out as customers face prescription chaos

New study raises questions about niacin and heart health

hotspot

hotspot

explore

focus